Marc Frager
Boca Raton, FLNPI 1740394220
Payments from drug & device makers
$1,750in general payments, 2019–2025
Across 105 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$400
- Lilly USA, LLC$370
- AstraZeneca$205
- AbbVie$143
- Novo Nordisk$117
- Amgen$72
- plus $442 from 14 others
What the payments were for
- Food & beverage$1,742100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
21
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 26 | $400 |
| Lilly USA, LLC | 24 | $370 |
| AstraZeneca | 11 | $205 |
| AbbVie | 8 | $143 |
| Novo Nordisk | 7 | $117 |
| Amgen(2 entities) | 4 | $72 |
| Merck | 4 | $71 |
| Insulet Corporation | 3 | $56 |
| Boehringer Ingelheim | 2 | $38 |
| Amneal Pharmaceuticals LLC | 3 | $38 |
| Shire North American Group Inc | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Lifescan, Inc. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Companion Medical, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.